A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2028

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

ARX788

HER2 antibody-drug conjugate

DRUG

Pyrotinib maleate

EGFR/HER2 dual inhibitor

DRUG

Trastuzumab

anti-Her2 monoclonal antibody

DRUG

Pertuzumab

anti-HER2 monoclonal antibody

DRUG

Docetaxel

Cytotoxic chemotherapy

DRUG

Carboplatin

Cytotoxic chemotherapy

Trial Locations (1)

Shengjing Hospital affiliated to China Medical University, Shenyang

All Listed Sponsors

lead

Caigang Liu

OTHER